NGL Fine-Chem Limited (BOM:524774)

Market Cap	17.22B +153.1%
Revenue (ttm)	5.01B +36.0%
Net Income	481.27M +127.8%
EPS	77.90 +127.8%
Shares Out	6.18M
PE Ratio	35.78
Forward PE	n/a
Dividend	1.75 (0.06%)
Ex-Dividend Date	Aug 18, 2026

Volume	1,054
Open	2,695.00
Previous Close	2,700.65
Day's Range	2,695.00 - 2,874.00
52-Week Range	985.05 - 3,000.00
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	May 21, 2026

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltra...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 520
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524774

Financial Performance

In fiscal year 2026, NGL Fine-Chem's revenue was 5.01 billion, an increase of 36.03% compared to the previous year's 3.68 billion. Earnings were 481.27 million, an increase of 127.83%.